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1.23 95%CI -1.35-1.11, P0.00001), TG (WMD-0.50, 95%CI -0.73-0.27,
P0.00001); and statinmetforminwasmore effective thanmetformin in lowering
LDL (WMD--0.84, 95%CI: -1.33-0.354, P0.0009), TC (WMD-1.28, 95%CI:
-1.47-1.10 P0.00001), and TG (WMD-0.27, 95%CI: -0.36-0.19, P0.00001). Het-
erogeneities were detected during the meta-analysis. CONCLUSIONS: Statins can
positively reduce the concentration of total testosterone, TC, TG and LDL. It cannot
be concluded, however, that statins have the long-term benefit. A large-scale, well-
designed, randomized controlled study is needed to ascertain this uncertainty.
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OBJECTIVES: To describe characteristics of T2DM patient subgroups who were more
likely to achieve HbA1c goal 7%with combination treatment of DPP4i with PIO orwith
METusingapredictivemodel.METHODS: Stepwise logistic regressionwas applied to
MarketScan claims data to develop a predictive model that estimated the proba-
bilities of HbA1c goal achievement in patients receiving DPP4i combinations. Sam-
ple selection criteria included: 1) T2DM diagnosis; 2) treatment of DPP4i with PIO or
with MET; 3) baseline HbA1c  7%; and 4) with one-year continuous enrollment.
Patients were ranked by the probabilityof achieving HbA1c7% and grouped into
cumulative percentiles; baseline characteristics of the optimal subgroups identi-
fied as the first 20th and 80th percentiles were reported. RESULTS: A total of 328
patients were included. The predictive model showed that patients who had neu-
ropathy, cerebrovascular conditions, or higher total medication use at baseline
were less likely to achieve goal on DPP4i combinations while patients with self
monitoring blood glucose use at baselineweremore likely to achieve goal (P 0.05).
The 80th percentile subgroup (n270) had a goal reaching rate of 57.0%,mean age of
50.3 years old, 44.3% female, 38.5% on MET, 13.8% on thiazolidinedione (TZD), and
HbA1c  9.13% at baseline. The 20th percentile subgroup (n83), achieved goal at
the rate of 72.3%, mean age of 50.6 years old, 46.1% female, 53.9% onMET, 25.7% on
TZD, and HbA1c  8.96% at baseline. CONCLUSIONS: Predictive factors for reaching
goal include: 1) use of self monitoring blood glucose, and 2) lack of neuropathy, cerebro-
vascular disease, or usage of medications. Subgroups that might benefit the most from
DPP4i treatment were identified. These patients exhibited a higher likelihood of having
prior use ofMET or TZD, and baseline HbA1c less than 9.0%.
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OBJECTIVES: To assess the relative efficacy and safety of fixed dose combinations
(FDCs) of anti-diabetic drugs in treatment naïve patients with type 2 diabetes mel-
litus (T2DM) using networkmeta-analysis technique.METHODS: Randomized con-
trolled trials, evaluating FDCs in treatment naïve patients with T2DM were
searched via Embase® and MEDLINE®. The abstracts were reviewed and data ex-
tractions were conducted by two independent reviewers. The outcomes of interest
included reduction in Hb1Ac levels, patients with HbA1c7%, fasting plasma glu-
cose (FPG) levels, and incidence of hypoglycemia. A network meta-analysis using
WinBUGS® was performed to combine the reported direct and indirect evidence
and a probability ranking for the included combinations was generated. RESULTS:
Eleven trials (n5781 patients) comparing the following FDCs: sulfonylureas/bigua-
nides (SUL/BGU), thiazolidinediones/biguanides (TZD/BGU), dipeptidyl peptidase-4
inhibitors/biguanides (DPP-4/BGU), alpha-glucosidase inhibitors/biguanides (AGI/
BGU), and thiazolidinediones/sulfonylureas (TZD/SUL) were included. Following
network meta-analysis using BGU, TZDs, and SUL as common comparators, TZD/
SUL was observed to be significantly better in terms of patients with HbA1c7%
than other FDCs [relative risk; 95% credible intervals vs. SUL/BGU (1.16; 1.03-1.3), vs.
TZD/BGU (1.12; 1.01-1.24), and DPP-4/BGU (1.18; 1.07-1.29)]. Statistically, however,
non-significant differenceswere observed among the FDCs other than TZD/SUL for
this outcome. All FDCs achieved clinically meaningful reductions in HbA1c and
FPG, though the differences between the FDCs were statistically non-significant.
According to the probability ranking for reduction in HbA1c and FPG levels, the
rank favored TZD/SUL followed by AGI/BGU, TZD/BGU, SUL/BGU, and DPP/BGU.
The probability of occurrence of hypoglycemia was highest with SUL/BGU (78.3%)
followed by TZD/SUL (20.2%), TZD/BGU (0.03%), and DPP-4/BGU (0.005%). Incidence
of hypoglycemiawas not reported for AGI/BGU. CONCLUSIONS: Clinically, all FDCs
effectively achieved glycemic control in patients with T2DM, however, the risk
ratios from network meta-analysis were inconclusive to determine the relative
efficacy of these FDCs. The probability ranking suggested the potential use of TZD/
SUL in treatment naïve T2DM patients.
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OBJECTIVES: Obesity and type 2 diabetes mellitus (T2DM) are major health issues
in developing countries contributing to increased morbidity and mortality. Bariat-
ric surgery is an effective procedure leading to durable weight loss in morbidly
obese patients, while metabolic surgery aims at resolving T2DM. The objective of
our study was to assess the efficacy and safety of those procedures in Indians.
METHODS: A comprehensive search was performed in PUBMED and websites of
Indian medical databases and journals (www.indmed.org, www.dmri.in, www.n-
mji.in, www.japi.in). Studiesmet the inclusion criteria if they enrolled Indian obese
patients with or without T2DM undergoing following laparoscopic procedures:
sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, single-
incision sleeve gastrectomy. RESULTS: Our search retrieved nine studies (978 pa-
tients) of which three included T2DM patients (N  91) exclusively. Postoperative
excessive weight loss ranged from 59.1% to 76.1% after 12-months and from 65.2%
to 71.1% after 24-months of follow-up. BMI was reduced by 5.9-20.5 kg/m2, dyslip-
idemia was resolved in 34-100% patients and hypertension was improved in 67-
95% individuals around one year after surgery. Moreover, at the same time joint
pain was reduced in 57-97% patients and sleep apnea in 100% subjects. The inci-
dence of asthma and depression were also reduced following bariatric/metabolic
surgery.Metabolic procedures carried out in the subset of diabeticswere associated
with T2DM resolution in 61-100% of patients, reduction of HbA1c by 2.3-4.0 per-
centage points and improvement in fasting blood glucose by 60-144 mg/dl. Reduc-
tion of BMI among diabetics was in the range between 5.9–9.8 kg/m2. Rates of
postoperative complications were generally low and only one death was reported
due to pulmonary embolism. CONCLUSIONS: Bariatric and metabolic procedures
are effective in both weight reduction as well as improvement or resolution of
T2DM. Those procedures are safe and beneficial in morbidly obese patients espe-
cially with T2DM.
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OBJECTIVES: Many studies have shown the distance from skin to muscle layer is
shorter than imagined; it’s important to ensure insulin injections are consistently
made into subcutaneous layer, without leakage/backflow or subject-reported in-
jection pain. The objective of this study was to assess clinical outcomes in T2DM
patients switched from insulin injection with longer pen needles (PNs) to shorter
PNs. METHODS: A retrospective study was conducted from July ’09 to Jan ’12 to
compare lipohypertrophy, bleeding, bruising, insulin leakage, pain, and bulge on
skin in a clinic in Yilan, Taiwan. Eighty-two patients with diabetes who were pre-
scribed injectable insulin were included. Before Jul ’09, all patients were prescribed
8 mm PNs. There was no limitation of insulin type, dosage, gender or education
level. From July 2009 to August 2011, PN length was switched to 5mm, then (begin-
ning Jul ’11) to 4mm. Injection techniques and injection areas were inspected by
certified diabetes educators every 3 months for all subjects. Standard injection
technique were taught and followed-up in patients. All statistical analyses were
conducted using SAS software (vs. 9.1).RESULTS:Demographic characteristics: age
60.514.3 years, 58.5% males, 92.7% T2DM, diabetes duration 16.07.0 years and
insulin injection duration 6.84.2 years. A1C: 8.31.5%, 8.11.2% and 8.11.1%
(p0.3180); BMI: 25.33.4kg/m2, 25.13.4kg/m2 and 25.435.4kg/m2 (p0.8565).
The bleeding/bruising decreased from 64.6% to 56.1% to 54.9% (p0.0904), lipohy-
pertrophy formation decreased from 26% to 20% to 15% (p 0.1954). Reports of
insulin leakage from tip or skin (p0.8715, 0.5644), pain perception (p0.1379) and
bulge on skin (p0.8039) were not statistically significant between 5mm and 4mm
PNs. CONCLUSIONS: No significant changes in A1C and BMI associated with
change in needle length from 8mm to 5mm and from 5mm to 4mmwere observed.
Therewas no apparent increase in leakage of insulin. A trend towards less bleeding
and pain was observed when using shorter needles.
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OBJECTIVES: Exenatide is a new antidiabetic agent which is an analog of incretin
(glucagon-like peptide 1) with a adjunctive therapy with type 2 diabetes mellitus
(T2DM),and has adverse events of nausea, vomiting and poor appetite. To assess
the clinical efficacy of exenatide in T2DM.METHODS: Inclusion criteria were T2DM
with inadequate glycemic control under oral antidiabetic agnets or insulin therapy.
Exenatide were added on by the reatment course of exenatide is 5g twice a day at
first month and then adjusted to 10g twice a day if tolerated. The primary out-
comes are influence on HbA1C level and body weight. RESULTS: Eighteen patients,
who were 7 male and 11 female with mean age of 43.46, were recruited. Of them
had a mean body weight of 97.15kg and mean HbA1C of 9.1%. HbA1c improved
significantly after 3 months and 6 months with mean reduction of 0.75%(p0.002)
and 0.97%(p0.009). Mean body weight mild decreased at 3 months (4.33 kg) and
reduced significantly at 4 months and 6 months with 5kg (p0.005) and 9.74kg
(p0.0006). CONCLUSIONS: Exenatide improve HbA1c and body weight greatly
within 6months in a local hospital andmayhave great affect on the changing of life
style, like diet control and frequency of Self-Monitoring of Blood Glucose. In future,
a larger and long time study would need to demonstrate the validity of exenatide
on the taiwanese.
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ROLE OF CHROMIUM IN TYPE-2 DIABETES THERAPY: A SYSTEMATIC REVIEW
STUDY
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